RA0015

antibody from Oursmab

Targeting: ANGPTL3 ANGPT5

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0015

Provider

Oursmab

Product name

Evinacumab (Biosimilar Reference Antibody) (ANGPTL3)

Antibody type

Monoclonal

Description

Evinacumab is a fully human monoclonal IgG4 antibody approved as an adjunct therapy for the treatment of homozygous familial hypercholesterolemia (HoFH) and severe forms of hypercholesterolemia. It represents a first-in-class therapeutic with a novel, non-statin mechanism. Evinacumab functions as a potent and selective inhibitor of angiopoietin-like protein 3 (ANGPTL3). By binding to and neutralizing ANGPTL3 in the bloodstream, evinacumab prevents ANGPTL3 from inhibiting two key enzymes involved in lipid metabolism: lipoprotein lipase (LPL) and endothelial lipase (EL). This inhibition leads to a dramatic reduction in all major atherogenic lipid fractions¡ªlow-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides¡ªthrough a mechanism that is independent of the LDL receptor pathway.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.